← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #480 OF 1,000 MOST-CITED

Acceptance of drug products

FDA cited this observation 39 times across 38 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs39
BY FISCAL YEAR
FY20263
FY20252
FY20247
FY20231
FY20225
FY20212
FY20202
FY20199
FY20182
FY20176

How FDA worded it — real examples

Determinations of conformance to appropriate written specifications for acceptance are deficient for drug products.

The Mentholatum Company · Orchard Park, New York · Drugs · 2026-03-23

Determinations of conformance to appropriate written specifications for acceptance are deficient for drug products.

Analytical Solutions · Navi Mumbai · Drugs · 2025-11-28

Determinations of conformance to appropriate written specifications for acceptance are deficient for drug products.

B. Braun US Pharmaceutical Manufacturing, LLC · Irvine, California · Drugs · 2025-11-21

Determinations of conformance to appropriate written specifications for acceptance are not made and deficient for drug products. Electronic records are used, but they do not meet requirements to ensure that they are trustworthy, reliable and generally equivalent to paper records.

APIPHARMA d.o.o · Nasice · Drugs · 2025-03-28

Determinations of conformance to appropriate written specifications for acceptance are not made for drug products.

Gussyup LLC · Henderson, Nevada · Drugs · 2025-02-20

Determinations of conformance to appropriate written specifications for acceptance are not made for drug products.

Airgas USA, LLC · Hyattsville, Maryland · Drugs · 2024-09-30

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →